Buy Brilinta Over-The-Counter

Warnings

It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

Interactions

Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Monitor therapy

Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. Monitor therapy

Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Avoid combination

Food interaction

Pregnancy

• Fluoroquinolones are not recommended during pregnancy, for lactating women or for children unless there are overriding reasons for their use.
• You and your healthcare provider should decide if you will continue to take Depakote or Depakene while you are pregnant.
• Do not use in pregnant or nursing pets.

Overview

The combined use of ticagrelor, levonorgestrel and ethinyl estradiol increases the exposure of ethinyl estradiol by about 20%, but does not affect the pharmacokinetics of levonorgestrel. No Brilinta significant effect on contraceptive effectiveness is expected with the simultaneous use of levonorgestrel, ethinyl estradiol and ticagrelor.

Medicines that can cause bradycardia

In connection with the identification of mainly asymptomatic ventricular pauses and bradycardia, you should be careful to take the drug Brilinta simultaneously with drugs that can cause bradycardia. However, in the PLATO study, there were no clinically significant adverse events when combined with one or more drugs that could cause bradycardia (for example, 96% of patients took beta-blockers at the same time, 33% slow calcium channel blockers, diltiazem and verapamil, and 4% - digoxin).

Other concomitant therapy

In clinical studies, the Brilinta drug was mainly prescribed in conjunction with ASA, about pump inhibitors, statins, beta-blockers, ACE inhibitors and angiotensin II receptor antagonists as part of a long-term administration for the treatment of concomitant diseases, as well as with heparin, low molecular weight heparins, II glycoprotein II inhibitors receptors for iv administration as part of short-term therapy. Based on the results of these studies, no clinically significant adverse interaction was detected.

The combined use of the Brilint drug with heparin, enoxaparin, or desmopressin did not affect APTT, activated clotting time (ABC), and factor Xa studies; however, due to potential pharmacodynamic interaction, caution should be exercised when combined with drugs that affect hemostasis.

In connection with reports of subcutaneous hemorrhage associated with the use of selective serotonin reuptake inhibitors (e.g., paroxetine, sertraline and citalopram), caution is advised when taken with ticagrelor, since there may be an increased risk of bleeding.

special instructions

Risk of bleeding

When prescribing the drug Brilint, patients with an increased risk of bleeding should assess the ratio of the benefits of preventing atherothrombotic complications and the risk of bleeding.

- predisposition of patients to the development of bleeding (for example, in connection with a recent injury, a recent operation, bleeding disorders, impaired liver function of moderate severity, active or recent bleeding from the digestive tract). The use of the drug Brilint is contraindicated in patients with active pathological bleeding, a history of intracranial hemorrhage, severe liver dysfunction;

- concomitant use of drugs that can increase the risk of bleeding (for example, NSAIDs, oral anticoagulants and / or fibrinolytics taken within 24 hours before taking Brilinta drug).

There is no evidence of hemostatic efficacy of platelet transfusions in patients with ticagrelor; circulating ticagrelor may inhibit transfused platelets in Brilinta blood. Because with the concomitant use of Brilint's drug and desmopressin, the standardized bleeding time did not decrease, it is unlikely that desmopressin https://zentherapycenter.com/let-k/ketopine-2.php effectively stop clinically significant bleeding.

Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and / or therapy with recombinant factor Vlla can increase hemostasis. After establishing the cause of bleeding and stopping it, therapy with ticagrelor can be resumed.

Before the planned operation or the start of taking new drugs, the patient should inform the doctor about taking the drug Brilint.

In the PLATO study in patients undergoing CABG, when using the Brilint drug, there was more bleeding compared with clopidogrel when therapy was stopped 1 day before surgery, but the incidence of major bleeding after discontinuation of therapy 2 or more days before surgery was similar in comparison with clopidogrel. If the patient undergoes a planned operation and an antithrombotic effect is not desired, then Brilint therapy should be discontinued 7 days before surgery.

Patients with Prior Ischemic Stroke

Patients with ACS with a previous ischemic stroke can take Brilinta for up to 12 months (PLATO study).

The PEGASUS study did not include patients with a history of myocardial infarction with a previous ischemic stroke. Therefore, in the absence of data, care should be taken with a duration of more than 1 year.